These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 8674161)

  • 21. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients.
    Avramis VI; Spence SA
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):239-47. PubMed ID: 17414566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
    Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
    Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application.
    Abu Lila AS; Eldin NE; Ichihara M; Ishida T; Kiwada H
    Int J Pharm; 2012 Nov; 438(1-2):176-83. PubMed ID: 22944302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liposomal doxorubicin.
    Tardi PG; Boman NL; Cullis PR
    J Drug Target; 1996; 4(3):129-40. PubMed ID: 8959485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peg-Grafted Liposomes for L-Asparaginase Encapsulation.
    de Souza Guimarães M; Cachumba JJM; Bueno CZ; Torres-Obreque KM; Lara GVR; Monteiro G; Barbosa LRS; Pessoa A; Rangel-Yagui CO
    Pharmaceutics; 2022 Aug; 14(9):. PubMed ID: 36145567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acrylic microspheres in vivo VI: antitumor effect of microparticles with immobilized L-asparaginase against 6C3HED lymphoma.
    Edman P; Sjöholm I
    J Pharm Sci; 1983 Jun; 72(6):654-8. PubMed ID: 6875826
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a liposomal formulation of the natural flavonoid fisetin.
    Mignet N; Seguin J; Ramos Romano M; Brullé L; Touil YS; Scherman D; Bessodes M; Chabot GG
    Int J Pharm; 2012 Feb; 423(1):69-76. PubMed ID: 21571054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
    Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
    J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes.
    Gabizon AA
    Cancer Res; 1992 Feb; 52(4):891-6. PubMed ID: 1737351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.
    Mayer LD; Tai LC; Ko DS; Masin D; Ginsberg RS; Cullis PR; Bally MB
    Cancer Res; 1989 Nov; 49(21):5922-30. PubMed ID: 2790807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liposomal formulations of a novel antitumor agent: drug loading and optimization.
    Pavliv L; Tyle P; Johnston A
    PDA J Pharm Sci Technol; 1995; 49(1):9-12. PubMed ID: 7757460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomes as carriers of different new lipophilic antitumour drugs: a preliminary report.
    Sampedro F; Partika J; Santalo P; Molins-Pujol AM; Bonal J; Perez-Soler R
    J Microencapsul; 1994; 11(3):309-18. PubMed ID: 8064554
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity.
    Shmeeda H; Amitay Y; Tzemach D; Gorin J; Gabizon A
    J Control Release; 2013 May; 167(3):265-75. PubMed ID: 23419948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors.
    Boman NL; Masin D; Mayer LD; Cullis PR; Bally MB
    Cancer Res; 1994 Jun; 54(11):2830-3. PubMed ID: 8187061
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Encapsulation of vinorelbine into cholesterol-polyethylene glycol coated vesicles: drug loading and pharmacokinetic studies.
    Li C; Cui J; Wang C; Zhang L; Xiu X; Li Y; Wei N; Li Y; Zhang L
    J Pharm Pharmacol; 2011 Mar; 63(3):376-84. PubMed ID: 21749385
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposome encapsulation reduces cantharidin toxicity.
    Chang CC; Liu DZ; Lin SY; Liang HJ; Hou WC; Huang WJ; Chang CH; Ho FM; Liang YC
    Food Chem Toxicol; 2008 Sep; 46(9):3116-21. PubMed ID: 18652872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of native Escherichia coli asparaginase.
    Borghorst S; Pieters R; Kuehnel HJ; Boos J; Hempel G
    Pediatr Hematol Oncol; 2012 Mar; 29(2):154-65. PubMed ID: 22376019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin.
    Abu Lila AS; Matsumoto H; Doi Y; Nakamura H; Ishida T; Kiwada H
    Eur J Pharm Biopharm; 2012 Aug; 81(3):524-31. PubMed ID: 22554766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantages in the use of L-asparaginase-albumin polymer as an antitumor agent.
    Poznansky MJ; Shandling M; Salkie MA; Elliott JF; Lau E
    Cancer Res; 1982 Mar; 42(3):1020-5. PubMed ID: 6895861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.